Abstract
Huntington's Disease (HD) is a fatal autosomal dominant neurodegenerative disorder with no approved disease-modifying therapy. We applied a computational drug repurposing pipeline to single-cell RNA sequencing data from HD patient caudate/putamen tissue (GSE165030; 1,120 cells; 7 clusters). Differential expression analysis identified 340 HD-dysregulated genes, from which 91 ChEMBL-tractable targets were extracted spanning cytoskeletal regulators (VIM, MYH9, RAC1, CFL1, TAGLN2), immune regulators (HLA-A/B/C, PSMB8, PSME1, ISG15), chaperone/proteostasis proteins (CDC37, CLU, FKBP1A), and TGF-beta signaling (TGFBR2). Systematic screening of 16,223 unique bioactive compounds with USPTO prior art verification identified all 16,223 as NOVEL_ALL (100%). Top leads: CHEMBL5653589 (33 targets, final score 339.6 — the highest composite score across the Ritschel Research portfolio of 28 patents), CHEMBL3752910 (22 targets, score 228.7), MOLIBRESIB (CHEMBL1232461, BET bromodomain inhibitor, 11 targets, score 118.0), DASATINIB (CHEMBL5416410, FDA-approved, score 48.3), and LESTAURTINIB (CHEMBL603469, score 47.8). Critical cross-disease convergence: CHEMBL5653589 and MOLIBRESIB were independently identified as top candidates in both this HD caudate/putamen pipeline and the inventor's prior ALS spinal cord pipeline (Patent 27, GSE153960), establishing pan-neurodegenerative therapeutic relevance across anatomically and mechanistically distinct neurodegenerative conditions. TGFBR2 emerges as a high-priority HD target present in 6 of the top 10 compounds. These findings are the basis of a filed USPTO provisional patent application (Ritschel Research, Micro-Entity, March 2026). Provisional patent specification: [add spec DOI after upload]. Pipeline code: https://github.com/glenritschel/huntingtons-scrna